Samuel Kintz

President and CEO, Director, Enliven Therapeutics, Inc.

Bought, 12 months

$0.0M

Sold, 12 months

$0.3M

Companies

Latest trade

Nov 17, 2025

Companies

Enliven Therapeutics, Inc.President and CEO, Director −$0.5M

Trades

ELVN Sold 12,500 shares at $21.82 · planned $0.3M Nov 17

ELVN Sold 12,500 shares at $21.33 · planned $0.3M Oct 17

Open-market trades from SEC Form 4 only: no grants, option exercises or gifts. People are matched by the name on their filings, so two people with the same name share this page. For information only — not investment advice.